What will be the total USD sales for Hibsago in the U.S. during its first full year of market availability?

Hibsago was approved by the FDA on October 20, 2026. Its first full year of market availability would therefore be October 21, 2026, through October 20, 2027.

Forecasted on

Forecast probabilities

  • Less than $50 million: 29.3%
  • $50 to $150 billion: 41.5%
  • $150 to $250 million: 17.3%
  • $250 to $500 million: 8.8%
  • More than $500 million: 3.3%

Reasoning

Hibsago’s most likely first-year U.S. sales outcome is the listed $50 to $150 billion bin, with a 41.5% probability; that label appears to be a typo for $50–$150 million. The chance of sales below $50 million is 29.3%, while the probabilities are 17.3% for $150–$250 million, 8.8% for $250–$500 million, and 3.3% for more than $500 million. The balance points to a meaningful but uncertain launch: a genuinely novel treatment, constrained by a narrow eligible population and real-world access hurdles.

Less than $50 million — 29.3%

A slow start is plausible. Although roughly 1.7 million U.S. residents are estimated to have chronic hepatitis B, Hibsago is for a much smaller group: adults without cirrhosis who have already taken antivirals, achieved viral suppression, and meet a specified HBsAg threshold. Patients must also be identified and tested, and Roche’s companion diagnostic was only recently authorized [a2, a4, a5, e11].

The treatment offers a meaningful possibility of functional cure, but not a guarantee: 19% of trial participants achieved it, and most did not. Boxed warnings for liver reactions and platelet declines, along with frequent laboratory monitoring, could make patients and clinicians cautious. Self-administration after the first dose may ease logistics, but does not remove the monitoring burden [a4, a8, e15, e17, e18]. With no U.S. price or payer-coverage details reported, the launch could be held back further while access pathways take shape [a4, a6].

$50 to $150 billion — 41.5%

This is the central case, understood as the intended $50–$150 million range. Hibsago is the first approved treatment of its kind in the United States, and its trial results offer something standard antivirals rarely do: a chance to stop treatment after achieving functional cure. The FDA’s approval was based on results showing a 19% cure rate overall and 26% among patients with lower baseline HBsAg; 24% of treated patients qualified to stop their existing antivirals [e4, e10, e14, e16].

That differentiation could sustain specialist interest even if adoption builds gradually. A companion diagnostic is authorized, and patients can self-administer after their first dose. But the eligible population is limited, most patients do not achieve functional cure, and neither U.S. pricing nor coverage is yet established [a2, a5, a8, e11, e18]. These forces make a moderate first-year result more likely than either a very small launch or a rapid blockbuster ramp.

$150 to $250 million — 17.3%

A stronger launch could reach this range if specialists quickly identify eligible patients and the novel treatment benefit outweighs the monitoring burden. The companion diagnostic may help make patient selection more practical, while GSK’s commercial capacity and Jefferies’ £2.2 billion peak annual sales forecast point to substantial longer-term expectations [e5, e11, e13].

But peak sales are not first-year U.S. sales. Reaching this outcome would require early uptake and favorable pricing despite a narrow label, frequent monitoring, and uncertainty about reimbursement. Japan’s reported reimbursement price offers a reference point, not a reliable estimate of U.S. course revenue [a4, a6].

$250 to $500 million — 8.8%

This outcome would require the launch to move unusually quickly: a large number of eligible patients starting treatment, strong specialist adoption, and sufficient revenue per course. Hibsago’s first-in-class status and the chance of functional cure provide a basis for optimism; self-administration after the first dose could also support wider use [e4, e10, e18].

The counterweight is that a six-month injectable course is not a chronic therapy that automatically accumulates recurring revenue. Eligibility is restricted, and monitoring, testing, and payer approval could all slow starts. The available evidence supports commercial potential, but does not establish the pace or price needed for this level of first-year sales [a2, a4, e17].

More than $500 million — 3.3%

A result above $500 million is possible, but it would require exceptional early uptake and high U.S. revenue per patient. Jefferies’ peak-sales forecast and the first-in-class treatment benefit show why the long-term opportunity attracts attention; they do not demonstrate that a narrow, newly approved indication can generate blockbuster sales in its first full year [e5, e12].

The sales estimate remains especially uncertain because U.S. pricing and coverage details are unavailable. Monitoring requirements, the companion diagnostic, and the limited pool of eligible patients make this the least likely outcome [a4, a6, e11, e17].

Why the probabilities favor a moderate launch

The largest probability goes to the listed $50 to $150 billion bin, with a substantial chance of falling below it and progressively smaller chances of higher sales. That distribution reflects both sides of the evidence: Hibsago’s clinical differentiation may motivate uptake, but eligibility restrictions, monitoring, and unresolved access and pricing questions are meaningful obstacles. Jefferies’ peak-sales forecast supports the possibility of a large eventual market, not a conclusion that first-year U.S. sales will reach that scale [e5].

Cited evidence